Mr. Hahn has more than 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as executive director of finance at Middlebrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly-traded specialty pharmaceutical company.
Graybug Vision files for $86 Million IPO on NASDAQ (GRAY)
Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising [….]
BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]
Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO October 3, 2019 It has been just 20 months since Viela Bio was founded and today Viela Bio CEO [….]
Viela Bio Becomes Latest Biotech Intent on Going Public with $150M Offering AstraZeneca spinout files for IPO on Nasdaq August 29, 2019 Viela Bio, the AstraZeneca spin-off biotech, has captured [….]
